Myth: immunotherapy is only for the rich — partly true, and getting less true every year

Not always, though it is genuinely expensive for most families without some form of support. A full course of modern immunotherapy is a significant, often five- or six-figure rupee expense as of August 2026 — the exact amount depends heavily on which drug is used, the dose, how many cycles are needed, and whether it's combined with chemotherapy. Any specific figure quoted online, including this one, is indicative only and not a quote for your treatment.

What the flat "only for the rich" version of this myth misses is that very few families actually pay the full, undiscounted cost out of pocket from the first cycle to the last. Health insurance, government scheme reimbursement, hospital EMI plans, pharmaceutical patient-assistance programmes and — most recently — a domestic biosimilar for one of the most widely used checkpoint inhibitors all change the real number a family ends up paying. Layer two or three of these together, and the gap between "unaffordable" and "manageable" often narrows considerably.

None of this means cost stops being a real, valid worry. It means the worry deserves a conversation about specific routes, not a blanket assumption that the door is closed before you've asked.

All figures referenced on this page are indicative, as of August 2026, and are not a quote — a specific estimate for your situation is something our team can walk you through directly.

1. 1

   Check your health insurance policy's oncology clause

   Many mediclaim and health insurance policies now cover immunotherapy administered as day care under an oncology or chemotherapy benefit, sometimes with sub-limits or pre-authorisation steps. Reading the exact clause, or asking your hospital's insurance desk to check pre-authorisation before treatment starts, tells you what genuinely applies rather than assuming full or zero cover.

2. 2

   Ask about government scheme eligibility

   Schemes such as Aarogyasri offer reimbursement ceilings for eligible categories at empanelled centres. The ceiling amount, and exactly which drugs or protocols it applies to, changes over time — treat any figure you've seen online as outdated until your hospital's scheme desk confirms the current one for your case.

3. 3

   Ask the hospital about EMI or financing plans

   Most hospitals offering immunotherapy also offer EMI or staged-payment financing, which spreads the cost across the treatment period instead of requiring it upfront. This doesn't reduce the total cost, but it changes whether a family can start treatment on time rather than delaying it while trying to arrange a lump sum.

4. 4

   Ask about patient-assistance programmes

   Some pharmaceutical companies run assistance programmes for specific drugs, which can reduce cost for patients who qualify under the programme's own criteria. Your treating oncologist or hospital pharmacy will know which, if any, currently apply to the specific drug you've been prescribed.

5. 5

   Ask specifically whether a biosimilar applies to your prescription

   Where a biosimilar exists for your specific drug, it can meaningfully change the total cost. This is worth asking your oncologist directly, since it depends on which molecule you've actually been prescribed, not on immunotherapy as a whole category.

The single biggest recent shift is around nivolumab, one of the most widely used checkpoint inhibitors across several cancer types. Its Indian patent protection lapsed in May 2026, and a domestic biosimilar launched in January 2026 at roughly a quarter of the reference product's price. That is a structural change in what the drug costs in India, not a temporary promotion — and it is the clearest example of why "immunotherapy is only for the rich" is becoming less true with time, at least for patients whose prescription includes this specific drug.

Pembrolizumab, the other widely used checkpoint inhibitor, does not have this option yet. Its patent protection is expected to begin lapsing only around 2028-29, so its cost picture has not shifted the same way and shouldn't be assumed to have changed just because a related drug's price has.

One caution worth taking seriously: as genuine biosimilars have entered the market ahead of patent expiry, counterfeit checkpoint inhibitors have also been reported entering the Indian market. Sourcing any checkpoint inhibitor, biosimilar or originator, only through a licensed hospital pharmacy with proper cold-chain handling and documentation is a patient-safety matter, not just a cost one — a lower price from an unverified source is not a saving worth the risk.

Financial stress makes any cheaper-sounding alternative more tempting, and that's understandable, not a failing. But some clinics and wellness providers specifically market lower-cost "immunity boosting" drips, high-dose supplement infusions, or similar practices to families who are already worried about affording evidence-based treatment. These practices have no peer-reviewed evidence of controlling cancer, and choosing one instead of prescribed immunotherapy because of cost doesn't save money on the outcome that matters most — it risks losing time that's genuinely hard to get back.

This is separate from traditional systems of wellbeing. Ayurveda, homeopathy, and similar traditions have real value for many families alongside cancer care, and using them for general wellbeing isn't something to be argued out of. The goal here is disclosure, not correction: telling your oncology team what you're taking or considering, including anything offered as a cheaper substitute for prescribed treatment, protects you either way — and it costs nothing to ask.

• Miracle Cure Stories on Social Media: How to Read Them — cost-anxious families are often the exact audience these posts are aimed at; here's how to read them critically.
• Myth: Immunotherapy Makes the Cancer Spread Faster — another common fear that can push families toward delaying or abandoning treatment, explained plainly.
• Myth: Immunotherapy Just Boosts Your Immunity — clears up what immunotherapy actually does, useful context before weighing its cost against an alternative.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION explains, delivers and monitors immunotherapy, including cost counselling, for patients.

This page is for general information and does not replace a consultation. Cost figures referenced here are indicative as of August 2026 and are not a quote — always confirm current insurance, scheme and pricing details directly with your hospital before deciding anything.

Most families ask about cost before they ask about anything else

Worrying about affording treatment isn't a sign you've failed to plan — it's the normal, first question. Ask us directly, and we'll go through your specific options honestly, at no cost.